Expert Insight
Robust Analytics for Novel Modalities: Industry Leaders Share Strategies
As cell and gene therapies, RNA-based platforms, and antibody-drug conjugates accelerate toward commercialization, the pharmaceutical industry must develop analytical methods robust enough to characterize increasingly complex therapeutic modalities while remaining flexible enough to evolve with emerging science. PharmaSource asked analytical
3 December 2025